Product Description
Nonprescription fluticasone nasal spray (Flonase Allergy) is used to relieve symptoms of rhinitis such as sneezing and a runny, stuffy, or itchy nose and itchy, watery eyes caused by hay fever or other allergies (caused by an allergy to pollen, mold, dust, or pets). Prescription fluticasone is also used to relieve symptoms of nonallergic rhinitis such as sneezing and runny or stuffy nose which are not caused by allergies.
Mechanisms of Action: LAB Agonist,Corticosteroid Hormone Receptor Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Inhalant,Nasal
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Germany, Greece, Hungary, India, Italy, Japan, Latvia, Mexico, Poland, Romania, Russia, Slovakia, South Africa, Spain, United States, Unknown Location
Active Clinical Trial Count: 34
Highest Development Phases
Phase 3: Asthma|Chronic Cough|Chronic Obstructive Pulmonary Disease|Conjunctivitis, Allergic|Inflammation|Nasal Polyposis|Rhinitis, Allergic|Rhinitis, Allergic, Perennial|Rhinitis, Allergic, Seasonal|Sinusitis
Phase 1: Respiratory Aspiration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-08-01 |
|
| Re-Open 3 | P3 |
Not yet recruiting |
Nasal Polyposis|Sinusitis |
2028-03-31 |
|
| ACT18301 | P2 |
Recruiting |
Asthma |
2027-10-12 |
|
| FpA-AS-30094 | P3 |
Unknown Status |
Asthma |
2026-12-31 |